31
total announcements
540788.BO · 15 min delayed
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has published its unaudited standalone financial results for the second quarter ended September 30, 2026, showing a net profit of ₹544.0 million and a total income from operations of ₹3,083.0 million.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has scheduled a Board Meeting on November 06, 2026, to consider and approve the Un-Audited Standalone Financial Results for the second quarter/half year ended September 30, 2026.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has issued a compliance certificate under regulation 74(5) of SEBI (DP) regulations, 2018, confirming the dematerialization of securities for the quarter ended September 30, 2026.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has received a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 for Jay Arvind Bhanushali, indicating a change in promoter holding. The disclosure shows Jay Arvind Bhanushali acquiring 2 shares, resulting in a total holding of 7,49,507 shares, representing 7.28% of the company's equity share capital.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Jay Arvind Bhanushali, a promoter of the company, regarding the acquisition of 1424 equity shares, representing 0.013% of the total share capital.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd disclosed the voting results of its 53rd Annual General Meeting, with all resolutions passed with the requisite majority.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd held its 53rd Annual General Meeting (AGM) on September 25, 2026, through video conferencing. The meeting was chaired by Dr. Haseeb Drabu, and all directors, statutory auditors, and secretarial auditors were present. The company reported a profit of INR 5.13 Lakhs compared to INR 207.26 Lakhs in the previous year. Members were informed about the remote e-voting facility and the results of e-voting will be displayed on the company's website.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has announced the closure of its trading window for dealing in securities from October 1, 2026, until the declaration of financial results for the half year ended September 30, 2026, and 48 hours thereafter. The company has informed the BSE that this is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct for Prevention of Insider Trading.
Aspira Pathlab & Diagnostics Ltd
Jay Arvind Bhanushali has acquired 1387 (0.013%) equity shares of Aspira Pathlab & Diagnostics Ltd through open market purchase between 11-09-2026 and 16-09-2026.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has formed a Right Issue Committee to raise up to Rs. 65 crore through a right issue to eligible equity shareholders, subject to shareholder and regulatory approval.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has announced the outcome of its Board Meeting, where it has approved raising funds up to Rs. 65,00,00,000 through a Right Issue to eligible equity shareholders, subject to shareholder and regulatory approvals.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has approved a right issue of up to Rs. 65 crore to eligible equity shareholders, subject to shareholder and regulatory approval. The company has also constituted a Right Issue Committee to proceed with the right issue and decide on its terms and conditions.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, related to Jay Arvind Bhanushali.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has dispatched a letter to non-email shareholders containing a weblink to access the Annual Report for the Financial Year 2025-26, as per Regulation 36(1)(b) of SEBI (LODR) 2015. The company has also announced the 53rd Annual General Meeting (AGM) to be held on September 25, 2026, through Video Conferencing (VC) facility.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has published a notice of its 53rd Annual General Meeting and E-voting details in newspapers and on its website. Additionally, a special window has been opened for re-lodging transfer deeds for physical shares. The company's property, Jai Ambe Chawl No. 3, has been attached by CapriGlobalCapitalLimited due to a debt of Rs. 4,50,999/-.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has submitted its Annual Report for the financial year 2025-26, including audited financial statements, to the BSE, as per the SEBI (LODR) Regulations, 2015.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has announced the notice of its 53rd Annual General Meeting (AGM) to be held on September 25, 2026, through video conferencing. The meeting will consider and adopt the audited standalone financial statements for the financial year ended March 31, 2026, and re-appoint Mr. Nikunj V Mange as a director. The meeting will also consider and approve a material related party transaction with M/s. Yashraj Research Foundation.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has announced the book closure date, notice of the 53rd Annual General Meeting, and e-voting date. The book closure will be from September 19, 2026, to September 25, 2026, and the e-voting period will be from September 22, 2026, to September 24, 2026.
Aspira Pathlab & Diagnostics Ltd
Aspira Pathlab & Diagnostics Ltd has announced the 53rd Annual General Meeting (AGM) to be held on September 25, 2026, through Video Conferencing/Other Audio-Visual Means. The notice and annual report for the financial year 2025-26 will be sent to shareholders via email, and also be available on the company's website and stock exchange websites.
Aspira Pathlab & Diagnostics Ltd
The BSE has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Jay Arvind Bhanushali for Aspira Pathlab & Diagnostics Ltd.